Next Article in Journal
Biological Analyses-Derived Translational Findings in the T Cell Receptor Alpha Chain Knockout Mouse as an Experimental Model for Ulcerative Colitis
Next Article in Special Issue
Review of OCT Angiography Findings in Diabetic Retinopathy: Insights and Perspectives
Previous Article in Journal
The Metastatic Capacity of Melanoma Reveals Alternative Pathways of Cancer Dissemination
Previous Article in Special Issue
Diabetic Retinopathy Screening Programme: Attendance, Barriers and Enablers amongst Young People with Diabetes Mellitus Aged 12–26 Years
Review

Challenges in Diabetic Micro-Complication Management: Focus on Diabetic Neuropathy

by 1,2,*, 1, 3,† and 4,†
1
Department of Pharmacy, Independent University, Dhaka 1229, Bangladesh
2
School of Biomedical Sciences, Ulster University, Coleraine BT52 1SA, UK
3
Department of Biotechnology, Graduate School, Konkuk University, Chungju 27478, Korea
4
Melbourne Dementia Research Centre, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3052, Australia
*
Author to whom correspondence should be addressed.
Authors contributed equally.
Academic Editor: Winfried M. Amoaku
Int. J. Transl. Med. 2021, 1(3), 175-186; https://0-doi-org.brum.beds.ac.uk/10.3390/ijtm1030013
Received: 25 August 2021 / Revised: 26 September 2021 / Accepted: 28 September 2021 / Published: 6 October 2021
(This article belongs to the Special Issue Diabetic Retinopathy)
The progression of diabetes leads to macro and microvascular complications, including diabetic neuropathy, which is the most prevalent microvascular complication with diabetes. Clinical manifestations of diabetic neuropathy begin with the loss of distal sensory function, pain, and substantial morbidity. It has been evident that ~50% of diabetic patients develop neuropathy at a certain stage in their lifetime. Interestingly, two major subtypes (type I and II) of diabetes do not share the same epidemiology and pathophysiology of diabetic neuropathy; thus, their management or treatment strategies may vary from each other. The past few decades of research suggest that many etiological features, diagnosis, and management complexities depend on the type of diabetes. However, the underlying mechanism of neuropathy in type I and type II diabetes remains unclear. This review provides the current knowledge on successful assessment, management, and pharmacological biomarkers to explore the treatment and surpass current challenges in diabetic neuropathy. View Full-Text
Keywords: type I and type II diabetes; microvascular complications; diabetic neuropathy; therapy and challenges type I and type II diabetes; microvascular complications; diabetic neuropathy; therapy and challenges
Show Figures

Figure 1

MDPI and ACS Style

Ansari, P.; Hannan, J.M.A.; Azam, S.; Jakaria, M. Challenges in Diabetic Micro-Complication Management: Focus on Diabetic Neuropathy. Int. J. Transl. Med. 2021, 1, 175-186. https://0-doi-org.brum.beds.ac.uk/10.3390/ijtm1030013

AMA Style

Ansari P, Hannan JMA, Azam S, Jakaria M. Challenges in Diabetic Micro-Complication Management: Focus on Diabetic Neuropathy. International Journal of Translational Medicine. 2021; 1(3):175-186. https://0-doi-org.brum.beds.ac.uk/10.3390/ijtm1030013

Chicago/Turabian Style

Ansari, Prawej, J.M.A. Hannan, Shofiul Azam, and Md. Jakaria 2021. "Challenges in Diabetic Micro-Complication Management: Focus on Diabetic Neuropathy" International Journal of Translational Medicine 1, no. 3: 175-186. https://0-doi-org.brum.beds.ac.uk/10.3390/ijtm1030013

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop